DE69306940D1 - 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe - Google Patents

3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe

Info

Publication number
DE69306940D1
DE69306940D1 DE69306940T DE69306940T DE69306940D1 DE 69306940 D1 DE69306940 D1 DE 69306940D1 DE 69306940 T DE69306940 T DE 69306940T DE 69306940 T DE69306940 T DE 69306940T DE 69306940 D1 DE69306940 D1 DE 69306940D1
Authority
DE
Germany
Prior art keywords
monophosphoryl lipid
vaccines containing
deacylated monophosphoryl
hepatitis vaccines
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69306940T
Other languages
English (en)
Other versions
DE69306940T2 (de
DE69306940T3 (de
Inventor
Nathalie Marie- Garcon-Johnson
Pierre Hauser
Clothilde Thiriart
Pierre Voet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69306940(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of DE69306940D1 publication Critical patent/DE69306940D1/de
Publication of DE69306940T2 publication Critical patent/DE69306940T2/de
Application granted granted Critical
Publication of DE69306940T3 publication Critical patent/DE69306940T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69306940T 1992-03-27 1993-03-24 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe Expired - Lifetime DE69306940T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
PCT/EP1993/000712 WO1993019780A1 (en) 1992-03-27 1993-03-24 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a

Publications (3)

Publication Number Publication Date
DE69306940D1 true DE69306940D1 (de) 1997-02-06
DE69306940T2 DE69306940T2 (de) 1997-06-26
DE69306940T3 DE69306940T3 (de) 2002-09-19

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69306940T Expired - Lifetime DE69306940T3 (de) 1992-03-27 1993-03-24 3-0-deacyliertes Monophosphoryl-Lipid-A enthaltende Hepatitis-Impfstoffe

Country Status (28)

Country Link
EP (1) EP0633784B2 (de)
JP (1) JP3470719B2 (de)
KR (1) KR100270134B1 (de)
CN (1) CN1072963C (de)
AP (1) AP570A (de)
AT (1) ATE146678T1 (de)
AU (4) AU3751693A (de)
CA (1) CA2132833C (de)
CZ (1) CZ283424B6 (de)
DE (1) DE69306940T3 (de)
DK (1) DK0633784T4 (de)
ES (1) ES2098029T5 (de)
FI (1) FI110843B (de)
GR (1) GR3022174T3 (de)
HK (1) HK1003218A1 (de)
HU (1) HU221253B1 (de)
IL (1) IL105161A (de)
MA (1) MA22842A1 (de)
MY (1) MY111880A (de)
NO (1) NO309458B1 (de)
NZ (1) NZ249868A (de)
RU (1) RU2121849C1 (de)
SA (1) SA93130573B1 (de)
SG (1) SG48375A1 (de)
SI (1) SI9300149B (de)
SK (1) SK280160B6 (de)
UA (1) UA44688C2 (de)
WO (1) WO1993019780A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
IL137998A0 (en) * 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP1126876B1 (de) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2540770T3 (es) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
TW200722101A (en) 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
CA2628328A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PT1962899E (pt) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Vacina conjugada polissacarídica pneumocócica
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3753574A1 (de) 2006-01-27 2020-12-23 Seqirus UK Limited Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
EP2010537B1 (de) 2006-03-23 2011-12-28 Novartis AG Imidazochinoxalinverbindungen als immunmodulatoren
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EA020459B1 (ru) 2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
EP4144368A1 (de) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
EP3313439A2 (de) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenetisch angepasste influenza-impfstoffe
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
EP0563091A1 (de) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Impfstoffe auf basis hepatitis-b-oberflächenantigen

Also Published As

Publication number Publication date
AU3397499A (en) 1999-08-19
GR3022174T3 (en) 1997-03-31
EP0633784B2 (de) 2001-10-17
SG48375A1 (en) 1998-04-17
KR100270134B1 (ko) 2000-10-16
SK115294A3 (en) 1995-06-07
AU6445796A (en) 1996-11-07
HK1003218A1 (en) 1998-10-16
ES2098029T5 (es) 2002-03-16
RU94042386A (ru) 1996-08-20
IL105161A0 (en) 1993-07-08
ES2098029T3 (es) 1997-04-16
CZ235594A3 (en) 1995-02-15
CZ283424B6 (cs) 1998-04-15
SI9300149A (en) 1993-12-31
EP0633784A1 (de) 1995-01-18
AP9300502A0 (en) 1993-04-30
NO943571D0 (no) 1994-09-26
CN1085805A (zh) 1994-04-27
AU767755B2 (en) 2003-11-20
MY111880A (en) 2001-02-28
SK280160B6 (sk) 1999-09-10
AU1000802A (en) 2002-02-21
HUT69931A (en) 1995-09-28
CA2132833C (en) 2007-03-06
KR950700757A (ko) 1995-02-20
DK0633784T3 (da) 1997-01-20
JP3470719B2 (ja) 2003-11-25
WO1993019780A1 (en) 1993-10-14
CA2132833A1 (en) 1993-10-14
RU2121849C1 (ru) 1998-11-20
NZ249868A (en) 1997-03-24
FI944442A (fi) 1994-09-26
ATE146678T1 (de) 1997-01-15
AU3751693A (en) 1993-11-08
FI944442A0 (fi) 1994-09-26
DE69306940T2 (de) 1997-06-26
AP570A (en) 1996-11-29
MA22842A1 (fr) 1993-10-01
HU221253B1 (en) 2002-09-28
HU9402758D0 (en) 1994-12-28
DK0633784T4 (da) 2001-12-31
NO943571L (no) 1994-11-14
JPH07505372A (ja) 1995-06-15
IL105161A (en) 1998-08-16
SI9300149B (sl) 2003-02-28
EP0633784B1 (de) 1996-12-27
DE69306940T3 (de) 2002-09-19
NO309458B1 (no) 2001-02-05
CN1072963C (zh) 2001-10-17
UA44688C2 (uk) 2002-03-15
SA93130573B1 (ar) 2004-08-31
FI110843B (fi) 2003-04-15

Similar Documents

Publication Publication Date Title
ATE146678T1 (de) 3-0-deacyliertes monophosphoryl-lipid-a enthaltende hepatitis-impfstoffe
DK0812593T3 (da) Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
CY2007016I2 (el) Εμβολιο ιου θηλωματος
GR3024242T3 (en) Vaccines
HK38293A (en) Hepatitis c virus
GB2212511B (en) Hepatitis c virus
IL79740A0 (en) Hepatitis vaccine
GB9215233D0 (en) Vaccines
GB9214871D0 (en) Vaccines
ZA93919B (en) Vaccines
GB9226768D0 (en) Vaccines
GB9020799D0 (en) Viral vaccines
GB9324964D0 (en) Viral vaccines
GB8712042D0 (en) Virus & vaccine
IL94510A0 (en) Influenza vaccine
GB9226283D0 (en) Vaccines
GB9221891D0 (en) Vaccines
GB9112796D0 (en) Nucleic acids
GB9206789D0 (en) Vaccine
GB9222156D0 (en) Vaccine
GB9206788D0 (en) Vaccine
GB9206797D0 (en) Vaccine
GB9213308D0 (en) Vaccine

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings